The purpose of the aPCC-emicizumab safety study is to investigate the hemostatic efficacy as measured by thrombin generation, of a low personalized dose of aPCC (FEIBA) in children and adults with hemophilia A and inhibitors on emicizumab prophylaxis.

开始日期2025-10-01

申办/合作机构

Emory University

[+1]

NCT07158606

/ Not yet recruiting临床4期

Understanding Treatment Outcomes and Immunologic Mechanisms in ALtuviiio Immune Tolerance Induction

The goal of this clinical trial is to learn how well Altuviiio (efanesoctacog alpha) works for Immune Tolerance Induction (ITI) while using Hemlibra (emicizumab) to prevent bleeds.
Participants will be given Altuviiio for their ITI therapy and also be treated with Hemlibra as standard of care prophylaxis to prevent bleeding. The research doctor will decide how much and how often the participant will get Hemlibra.
Participants will need to attend visits for checkups and tests. These visits are divided into 4 periods:
1. A screening period - 1 visit up to 8 weeks before the Treatment Period starts
2. ITI Treatment Period - 1 Baseline Visit plus Interim visits that occur every 4 weeks for up to 52 weeks. (Some of the interim visits may be done via phone)
3. Tapering Period - 5 visits at weeks 2, 4, 8, 12 and 16
4. Ongoing Monitoring Period - 4 visits at weeks 20, 30, 40 and 50

开始日期2025-10-01

申办/合作机构

Versiti, Inc.

NCT06998524

/ Recruiting临床3期

A Phase III, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Prophylaxis in Patients With Type 3 Von Willebrand Disease

This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been diagnosed with Type 3 von Willebrand disease (VWD). Participants on prior standard of care (SOC) on-demand therapy will be assessed via a randomized comparison (Arm A - emicizumab prophylaxis and Arm B - continuation of SOC on-demand therapy), while participants on prior SOC prophylactic therapy (Arm C - emicizumab prophylaxis) will be assessed via intra-participant analysis with data obtained from the preceding non-interventional study (NIS), WP45335 (NCT06883240).

开始日期2025-06-27

申办/合作机构

Hoffmann-La Roche Ltd.

100 项与艾美赛珠单抗相关的临床结果

登录后查看更多信息

100 项与艾美赛珠单抗相关的转化医学

登录后查看更多信息

100 项与艾美赛珠单抗相关的专利（医药）

登录后查看更多信息

713

项与艾美赛珠单抗相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Systematic review of cost-effectiveness modelling studies for haemophilia

Review

作者: Meier, Niklaus ; Ammann, Daniel ; Schwenkglenks, Matthias ; Probst, Jano ; Pletscher, Mark

AIMS:

Haemophilia is a rare genetic disease that hinders blood clotting. We aimed to review model-based cost-effectiveness analyses (CEAs) of haemophilia treatments, describe the sources of clinical evidence used by these CEAs, summarize the reported cost-effectiveness of different treatment strategies, and assess the quality and risk of bias.

METHODS:

We conducted a systematic literature review of model-based CEAs of haemophilia treatments by searching databases, the Tufts Medical Center CEA registry, and grey literature. We summarized and qualitatively synthesized the approaches and results of the included CEAs, without a meta-analysis due the diversity of the studies.

RESULTS:

32 eligible studies were performed in 12 countries and reported 53 pairwise comparisons. Most studies analysed patients with haemophilia A rather than haemophilia B. Comparisons of prophylactic versus on-demand treatment indicated that prophylaxis may not be cost-effective, but there was no clear consensus. Emicizumab was generally cost-effective compared with clotting factor treatments and was always dominant for patients with inhibitors. Immune tolerance induction following a Malmö protocol was found to be cost-effective compared to bypassing agents, while there was no consensus for the other protocols. Gene therapies as well as treatment with extended half-life coagulation factors were always cost-effective over their comparators. Studies were highly heterogenous regarding their time horizons, model structures, the inclusion of bleeding-related mortality and quality-of-life impacts. This heterogeneity limited the comparability of the studies. 19 of the 32 included studies received industry funding, which may have biased their results.

LIMITATIONS:

It was not possible to perform a quantitative synthesis of the results due to the heterogeneity of the underlying studies.

CONCLUSION:

Differences in results between previous CEAs may have been driven by heterogeneity in modelling approaches, clinical input data, and potential funding biases. A more consistent evidence base and modelling approach would enhance the comparability between CEAs.

2025-12-01·PROTEIN EXPRESSION AND PURIFICATION

Discovery and development of bispecific antibodies

Review

作者: Wakabayashi, Tetsuya ; Kuramochi, Taichi

Bispecific antibodies (BsAbs) represent a significant breakthrough in antibody-based therapeutics, offering the unique capability to engage two distinct targets simultaneously. BsAbs are expected to exert therapeutic effects that are unattainable with conventional antibody drugs. Specifically, they are being developed for use in intercellular bridging, proximity effects, dual target inhibition, and cell targeting dependent on two antigen types. In recent years, antibody drug discovery has made progress by taking advantage of this dual-targeting ability, and bispecific antibodies have been launched across multiple therapeutic areas. These include antitumor drugs intended to enhance T-cell killing activity and inhibit growth factors, drugs that mimic blood coagulation factor functions, and angiogenesis inhibitors. This review highlights the pivotal technological advancements that have overcome the manufacturing challenges associated with BsAbs, enabling the development of pharmaceutical-grade products. We use emicizumab as a case study to illustrate these developments. Particular emphasis is placed on the critical synergy between antibody engineering technology and protein purification technologies, which has played a crucial role in the successful production of BsAbs. Furthermore, we discuss recent innovations in affinity chromatography, specifically the development of alkaline-resistant Protein L resins that have significantly improved commercial production processes. We examine the unique affinity behaviors of these resins and their impact on BsAb purification. This comprehensive review aims to provide researchers and industry professionals with a thorough understanding of the current landscape and future potential of bispecific antibodies in therapeutic applications, highlighting both technical challenges and innovative solutions in this rapidly evolving field.

2025-11-01·EUROPEAN JOURNAL OF HAEMATOLOGY

Effectiveness of Octocog Alfa (BAY 81‐8973) to Treat People With Haemophilia A Enrolled in the ATHNdataset, Including Under‐Represented Subgroups

Article

作者: Recht, Michael ; Charlet, Jessica ; Moulton, Thomas ; Charafi, Lena ; Chandler, Martin

ABSTRACT:

Objectives:

To evaluate the real‐world effectiveness of octocog alfa (BAY 81‐8973; Kovaltry) in people with haemophilia A (PwHA), including under‐represented subgroups.

Methods:

We retrospectively analysed the American Thrombosis and Hemostasis Network (ATHN) dataset to identify the characteristics, treatment/clinical histories and annualised bleeding rates (ABRs) of PwHA receiving prophylactic or on‐demand octocog alfa. Subgroup analyses included females and those switching to octocog alfa. Data are reported descriptively.

Results:

Among 270 PwHA treated with octocog alfa with available bleeding rate data between 1 January 2010 and 31 October 2020, mean (standard deviation) total ABRs were low (0.59 [2.22]) and > 70% of those treated for > 12 months had 0 bleeds. At the second data cutoff (30 April 2022; n = 354), subgroups who switched to octocog alfa from previous treatment had low mean total ABRs after switching, including adolescents (0.83; n = 22), and those previously receiving emicizumab (0.17; n = 17). In females, 10/11 reported 0 bleeds, and of those with joint range of motion data available (n = 5), 100% had values ≥ 10% below the normal range in ≥ 2 joints.

Conclusions:

PwHA treated with octocog alfa in the ATHNdataset, including important subgroups, reported a low number of bleeds; thus, octocog alfa offers an effective therapeutic option.

465

项与艾美赛珠单抗相关的新闻（医药）

2025-09-30

·EndPoints

Star gets $125M Series D as it begins Phase 3 in bleeding disorders

Star Therapeutics patched together a $125 million Series D in what it thinks is pharma’s next big therapeutic category. The South San Francisco startup expects the funds to add a few years of runway and get its sole clinical-stage drug most of the way through a Phase 3 trial in von Willebrand disease while also expanding into other disorders, CEO Adam Rosenthal told Endpoints News . The experimental drug, called VGA039, is currently in a Phase 1/2 study testing multiple doses against placebo in patients with VWD. Rosenthal said Star will “probably show some of that data” at this year’s American Society of Hematology annual meeting in Orlando in December. The trial is fully enrolled. Star initiated an open-label Phase 3 , with patients expected to begin crossing over into that trial next year, Rosenthal said. It’s expected to have results from the 60-patient study in 2028, according to the US federal trials database. The inherited bleeding disorder can lead to bleeding in the joints, muscles, gastrointestinal tract, mouth and elsewhere. “One of the most overlooked aspects of the disease is heavy menstrual bleeding,” Rosenthal said. Patients’ periods “could last weeks or even months at a time with really, really heavy volume loss, which can also lead patients to be anemic and transfusion-dependent,” he said. He predicts that VWD could be “one of the next frontiers in benign heme.” “I&I has been the hot area for a while, but it’s quite competitive,” Rosenthal said. “So a lot of investors are targeting hematology as the next big therapeutic area and looking for assets there.” Takeda markets an enzyme replacement therapy known as Vonvendi for patients with VWD. Patients must receive IV infusions twice a week. That’s a large burden on patients, Rosenthal said. However, Star’s VGA039 could offer once-a-month dosing via an under-the-skin injection done by the patient at home, Rosenthal said. The monoclonal antibody targets Protein S with the goal of rebalancing blood clotting. He likened the category to the evolving hemophilia treatment market. Roche’s subcutaneous antibody, Hemlibra, is approved for hemophilia A. It’s the Swiss pharma’s second-largest product, with more than $5 billion in sales last year. “We think that the heme B space has just recently transitioned to subQ products in the last year. Now it’s time for VWD,” Rosenthal said. Pfizer’s hemophilia A and B treatment Hympavzi was greenlit last October . Some of Star’s team of 40-plus employees previously worked on multiple hemophilia programs, including Hemlibra, Rosenthal said. A few come from True North Therapeutics, which was bought by Bioverativ in 2017 and then, in turn, was acquired by Sanofi. The French pharma markets Enjaymo for a rare type of anemia called cold agglutinin disease, which was developed by True North. Sanofi is now reconnecting with Rosenthal and some former True Northers. The pharma’s corporate venture arm, which has a new $625 million commitment, is one of the main investors in the Series D round. Viking Global Investors, Janus Henderson Investors, Frazier Life Sciences, GordonMD Global Investments and others also took part. In the first half of 2026, Star will talk about expanding VGA039 into other indications, which will likely start with small Phase 2 trials, Rosenthal said. VGA039 used to be part of a Star business known as Vega Therapeutics , but it’s all part of one team now, Rosenthal said. The company also used to have a branch called Electra Therapeutics, but that biotech was spun out in 2023 when it independently raised $80 million , Rosenthal said. Electra is testing a monoclonal antibody for a rare condition known as secondary hemophagocytic lymphohistiocytosis.

临床3期并购上市批准

2025-09-30

·BioPharmaDive

Star raises another $125M for its blood disease drug

Star Therapeutics has raised $125 million in new venture funding that will help propel its experimental blood disease drug through late-stage testing.Initially formed as a hub-and-spoke biotech intending to build single-drug offshoots,Star is now primarily focused on a singular program for the blood disorder Von Willebrand disease. The company spun out one subsidiary, Electra Therapeutics, and has taken its top program,VGA039, from preclinical development to a Phase 3 trial,according to CEO and founder Adam Rosenthal.Von Willebrand disease is the most common bleeding disorder, affecting up to 1% of the U.S. population, according to the Centers for Disease Control and Prevention. Like hemophilia, the disease prevents the blood from clotting properly, leading to frequent bleeding episodes that can be really severe and disruptive to daily life, Rosenthal said.The treatment landscape for hemophilia has changed dramatically in recent years with the introduction of more convenient and longer-lasting preventive therapies. But innovation has moved more slowly in Von Willebrand, which is still largely treated with replacement clotting factors that require frequent infusions or injections.The pace appears to be picking up, however.The Food and Drug Administration expanded the use of a Takeda drug for Von Willebrand in September. Stars VGA039 is in advanced testing, as is Roches hemophilia drug Hemlibra. Privately held Hemab Therapeuticshas a therapy in early development, too.Adam Rosenthal is the founder and CEO of Star Therapeutics.Permission granted by Star TherapeuticsThere hasn't been any innovation because there hasn't been that recognition of the disease burden and the market potential, and I think now that is starting to change, Rosenthal said.Star is hoping VGA309 can become for Von Willebrand what Hemlibra one of Roches best-selling drugs is for hemophilia. Like Hemlibra, VGA309 is a preventive antibody drug thats meant to prevent bleeds for longer than available therapies and be administered through a subcutaneous injection.The drug is designed to target a molecule known as protein S, which, in turn, boosts the generation of a blood-clotting enzyme called thrombin.Unlike Hemlibra and Hemabs drug prospect, though, VGA309 might also be useful regardless of the type of Von Willebrand a patient has.We can treat all types of patients, and all types of bleeds, Rosenthal said.We're still in generation 1.0 and we're hoping to leapfrog all that incremental innovation and go straight to a subcutaneous therapy.Star presented interim results from an early-stage study at the American Society of Hematologymeeting last year. The findings got the attention of a lot of investors, Rosenthal said, and the company began pursuing a new funding round shortly afterwards.A Phase 3 trial began in September. Star is also exploring VGA039s potential in other blood disorders, though it hasnt yet disclosed specifics.Eighteen investors participated in Stars Series D round, which was co-led by Sanofi Ventures and Viking Global Investors.In a statement announcing the financing, Sanofi Ventures managing director Jason Hafler called VGA039 a compelling opportunity.Rosenthal said the company is open to commercializing VGA039 on its own or teaming with a pharmaceutical partner. Star hasnt ruled out an initial public offering either, he added.Its one of those rare circumstances where the market potential is so big,but the spend to get to market is actually quite small, Rosenthal said.It's something that an independent biotech can very easily do on their own.Star has raised more than $300 million since its inception in 2018, including a $90 million Series C round in 2023. '

临床3期临床结果

2025-09-29

·PRNewswire

Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors

If approved, Mim8 (denecimig) would offer the flexibility of treatment with a single-use, prefilled disposable pen injector with dosing options including once every month, once every two weeks, and once every week for people living with hemophilia A In hemophilia A, denecimig is designed to help the body form blood clots more effectively and was studied as part of the FRONTIER program across different dosing frequencies, age groups, severities, and with or without inhibitors1 Novo Nordisk is advancing its long-standing commitment to people living with hemophilia A, a potentially life-threatening condition BAGSVÆRD, Denmark and PLAINSBORO, N.J., Sept. 29, 2025 /PRNewswire/ -- Today, Novo Nordisk announced Mim8 (denecimig) has been submitted for review to the US Food and Drug Administration (FDA) through a Biologics License Application (BLA), a formal request to evaluate a biologic medicine. Denecimig is an investigational, next-generation bispecific antibody Factor VIIIa (FVIIIa) mimetic, designed as a preventive bleed routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital FVIIIa deficiency), with or without inhibitors.2 If approved, denecimig will be the first FVIIIa mimetic with flexible once every month, once every two weeks, and once every week dosing in a pre-filled, single-use pen, catering to the diverse needs of people living with hemophilia A, with or without inhibitors.1 "It is important that we continue to drive scientific advances in hemophilia A, and the FRONTIER program supports the potential of denecimig as a prophylaxis bleed treatment option for a range of patients across dosing frequencies, age groups, and condition severity, regardless of inhibitor status," said Anna Windle, Senior Vice President, Clinical Development, Medical & Regulatory Affairs at Novo Nordisk. "A cornerstone of hemophilia treatment is to help prevent bleeding episodes, and this submission is another step forward in our long-standing mission to help improve care. If approved, denecimig's single-dose prefilled injector pen and flexible dosing schedule may better fit into the lives of people living with this challenging condition." The FDA submission is grounded in the results from the FRONTIER study program, a comprehensive program of studies designed to establish the efficacy and safety profile of denecimig as a prophylaxis treatment to prevent or reduce the frequency of bleeding episodes in people with hemophilia A, with or without inhibitors.1,3-6 About Mim8 (denecimig) Mim8 (denecimig) is an investigational FVIIIa mimetic bispecific antibody designed with the aim to deliver once every month, once every two weeks, or once every week prophylaxis for people living with hemophilia A, with or without inhibitors.3-6 Denecimig, which is administered under the skin, "mimics" the role of FVIIIa by bridging Factor IXa and Factor X.7 This action replaces FVIIIa function, which helps restore the body's thrombin generation capacity, helping blood to clot.8 The use of denecimig in people living with hemophilia A is investigational and not approved by any regulatory authorities worldwide. About Hemophilia A Hemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.9 According to the World Federation of Hemophilia, it is estimated to affect approximately 836,000 people worldwide and hemophilia A is estimated to account for 80-85% of all hemophilia cases.10 There are different types of hemophilia, which are characterized by the type of clotting factor protein that is defective or missing.6 Hemophilia A is caused by a missing or defective clotting Factor VIII (FVIII).9 Some people with hemophilia A may develop inhibitors, an immune system response to the clotting factors used in replacement therapy, which can cause treatment to become ineffective.11 It has been estimated that approximately 30% of people living with hemophilia A have inhibitors.11 About the FRONTIER Clinical Program The FRONTIER clinical program includes FRONTIER1-5 and investigates denecimig as a preventive bleed treatment across pediatric and adult populations with hemophilia A, with or without inhibitors. 1,3-5,12,13 FRONTIER2, FRONTIER3 and FRONTIER4 formed the basis of the denecimig BLA submission. FRONTIER2 evaluated denecimig treatment once every month and once every week in adults and adolescents 12 years of age and older; FRONTIER3 evaluated denecimig treatment once every month and once every week in children below the age of 12; and FRONTIER4 was an open label extension trial evaluating the efficacy of denecimig once every two weeks (Q2W) as well as investigating the long-term safety of denecimig across all dosing regimens (once every month, once every two weeks, and once every week) in subjects with hemophilia A, with or without inhibitors.3-5 Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn, and YouTube. Contacts for further information References Novo Nordisk Data on File. Bowyer AE, Hickey K, Kitchen S, Ezban M. A next generation FVIII mimetic bispecific antibody, Mim8, the impact on non-factor VIII related haemostasis assays. Haemophilia. 2023;29(6):1633-1637. ClinicalTrials.gov. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors. Last accessed September 2025. Available at . ClinicalTrials.gov. A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors. Last accessed September 2025. Available at . ClinicalTrials.gov. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4). Last accessed September 2025. Available at . Østergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138(14):1258-1268. Lentz S, Chowedary P, Gil L, et al. FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. J Thromb Haemost. 2024;22(4): 990-1000. U.S. National Library of Medicine. F8 gene. MedlinePlus Genetics. Last accessed August 2025. Available at . MedlinePlus. Hemophilia. Last accessed September 2025. Available at . World Federation of Hemophilia. World Federation of Hemophilia Report on the Annual Global Survey 2023. Last accessed September 2025. Available at . Kim JY, You CW. The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A. Blood Res. 2019;54:204-209. ClinicalTrials.gov. A Research Study Investigating Mim8 in People With Haemophilia A (FRONTIER1). Last accessed September 2025. Available at . ClinicalTrials.gov. A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5). Last accessed September 2025. Available at . Novo Nordisk is a registered trademark of Novo Nordisk A/S. All other trademarks, registered or unregistered, are the property of their respective owners. © 2025 Novo Nordisk All rights reserved. US25HRBD00364 September 2025 Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床结果

100 项与艾美赛珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10821	艾美赛珠单抗	B02BX06	DB13923

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
凝血因子缺乏症	日本	Chugai Pharmaceutical Co., Ltd.	2018-03-23
血友病A	美国	Genentech, Inc.	2017-11-16

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血管性血友病3型	临床3期	美国	Hoffmann-La Roche Ltd.	2025-06-27
血管性血友病3型	临床3期	日本	Hoffmann-La Roche Ltd.	2025-06-27
血管性血友病3型	临床3期	比利时	Hoffmann-La Roche Ltd.	2025-06-27
血管性血友病3型	临床3期	加拿大	Hoffmann-La Roche Ltd.	2025-06-27
血管性血友病3型	临床3期	哥伦比亚	Hoffmann-La Roche Ltd.	2025-06-27
血管性血友病3型	临床3期	法国	Hoffmann-La Roche Ltd.	2025-06-27
血管性血友病3型	临床3期	德国	Hoffmann-La Roche Ltd.	2025-06-27
血管性血友病3型	临床3期	意大利	Hoffmann-La Roche Ltd.	2025-06-27
血管性血友病3型	临床3期	荷兰	Hoffmann-La Roche Ltd.	2025-06-27
血管性血友病3型	临床3期	波兰	Hoffmann-La Roche Ltd.	2025-06-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06155955 (Pubmed \| Haemophilia)	临床2/3期	血友病A	15	Low-dose Emicizumab	醖網醖蓋蓋襯鑰蓋淵餘(鑰簾夢蓋蓋蓋衊醖襯廠) = 顧鹽壓積構憲選窪餘蓋願蓋獵蓋鬱廠築憲獵範 (願衊糧網鬱壓選壓願鹹, -3 ~ 0)	积极	2024-12-31
ASH2024	N/A	血友病A	-	Emicizumab	繭獵製積構襯顧觸醖醖(顧壓憲齋顧憲範淵醖鏇) = 艱夢範積築糧觸鬱鏇構鏇齋憲蓋膚顧鏇願壓鹹 (鹽壓窪觸壓窪醖膚網憲, 1.1) 更多	-	2024-12-09
NCT04431726 (HAVEN 7, ASH2024)	临床3期	血友病A FVIII inhibitors	55	Emicizumab	餘積築獵製遞蓋願網範(憲鹹鑰蓋蓋襯觸艱鑰窪) = 鹽廠築積蓋鹽齋遞顧糧鏇觸顧築鏇繭遞鹽簾廠 (醖鹽製鏇積憲餘鬱齋築 )	积极	2024-12-08
NCT04431726 (HAVEN 7, ASH2024)	临床3期	血友病A FVIII inhibitors	55	Factor VIII	餘積築獵製遞蓋願網範(憲鹹鑰蓋蓋襯觸艱鑰窪) = 鏇廠艱鏇蓋築構繭窪鬱鏇觸顧築鏇繭遞鹽簾廠 (醖鹽製鏇積憲餘鬱齋築 )	积极	2024-12-08
JPRN-jRCTs041200037 (AKATSUKI, ASH2024)	临床4期	血友病A	12	艾美赛珠单抗	鑰範襯願憲廠淵蓋糧餘(淵壓獵膚壓壓構醖選襯) = 糧衊壓範醖鏇獵鹹憲範願夢鬱鏇獵齋壓窪壓壓 (網鹹憲繭獵糧範艱繭壓 )	积极	2024-12-08
HAVEN 7 (ASH2024)	临床3期	血友病A FVIII inhibitor	-	Emicizumab prophylaxis	製顧夢襯積製齋廠選製(鏇窪齋顧壓膚構襯繭廠): P-Value = $114,000/QALY	积极	2024-12-07
HAVEN 7 (ASH2024)	临床3期	血友病A FVIII inhibitor	-	Emicizumab (Standard of care (SOC) prophylaxis)	製顧夢襯積製齋廠選製(鏇窪齋顧壓膚構襯繭廠): P-Value = $114,000/QALY	积极	2024-12-07
ASH2024	N/A	血友病A	-	Emicizumab + ITI	築廠鹹觸願製鏇醖憲願(範鏇願遞鑰築鹹憲壓齋) = 糧夢窪餘網蓋鹽餘鹹製襯壓觸蓋齋鹹鑰艱鹹願 (窪襯窪鏇鹽廠簾鹹窪壓, 15 ~ 37) 更多	-	2024-12-07
Pubmed \| Haemophilia	N/A	血友病A	127	Standard dose of emicizumab	製鑰餘選製憲衊鏇艱艱(衊遞鏇遞積醖觸壓積鑰) = patients on emicizumab had significantly decreased annualized bleeding rate 範糧構鹹鬱膚簾憲鹹構 (範廠鹽衊壓衊遞衊蓋醖 ) 更多	积极	2024-07-01
ISTH2024	N/A	获得性血友病	233	Emicizumab	夢襯繭齋蓋鏇艱夢鏇餘(繭鏇簾鏇築獵衊窪鏇選) = 餘糧糧鹽範觸蓋顧衊築齋構鏇淵網願齋顧鏇獵 (淵製艱選憲範餘鏇獵壓 ) 更多	积极	2024-06-22
HAVEN 3，HAVEN 4 (Pubmed)	-	血友病A	191	艾美赛珠单抗	簾鑰網繭範鬱衊遞鏇範(製鏇簾窪夢構蓋餘醖鏇) = 齋夢壓膚衊繭艱製糧獵製願鏇簾簾製願窪網窪 (憲簾襯範蓋壓窪壓築艱 ) 更多	积极	2024-03-01
NCT03191799 (STASEY, Pubmed \| TH Open) 人工标引	临床3期	血友病A	56	Emicizumab prophylaxis with additional hemostatic medication	膚鏇顧範齋蓋願獵顧蓋(製鑰鏇憲窪願蓋襯網願) = 繭鹹蓋鬱鬱遞顧願廠鹽齋艱壓蓋鑰夢齋製顧衊 (餘願繭憲築鹽獵鏇簾選 ) 更多	积极	2024-01-12
NCT03191799 (STASEY, Pubmed \| TH Open) 人工标引	临床3期	血友病A	56	Emicizumab prophylaxis without additional hemostatic medication	膚鏇顧範齋蓋願獵顧蓋(製鑰鏇憲窪願蓋襯網願) = 願膚遞構積簾獵糧壓襯齋艱壓蓋鑰夢齋製顧衊 (餘願繭憲築鹽獵鏇簾選 )	积极	2024-01-12